Metropolitan Life Insurance Company (MetLife)’s Caribou Biosciences CRBU Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,652	Closed	-$23.9K	–	497
2024 Q1	$23.9K	Buy	4,652 +161	+4%	+$993	﹤0.01%	1770
2023 Q4	$25.7K	Hold	4,491	–	–	﹤0.01%	1803
2023 Q3	$21.5K	Buy	4,491 +1,213	+37%	+$7.53K	﹤0.01%	1859
2023 Q2	$13.9K	Hold	3,278	–	–	﹤0.01%	2119
2023 Q1	$17.4K	Sell	3,278 -354	-10%	-$2.21K	﹤0.01%	1958
2022 Q4	$22.8K	Hold	3,632	–	–	﹤0.01%	1940
2022 Q3	$38.3K	Hold	3,632	–	–	﹤0.01%	1635
2022 Q2	$19.7K	Hold	3,632	–	–	﹤0.01%	2061
2022 Q1	$33.3K	Sell	3,632 -2,065	-36%	-$21.8K	﹤0.01%	1824
2021 Q4	$86K	Hold	5,697	–	–	﹤0.01%	2555
2021 Q3	$136K	Buy	+5,697	New	+$139K	﹤0.01%	2342

Other funds holding CRBU

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CRBU Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Caribou Biosciences (CRBU) in Q2 2024, closing a stake of 4,652 shares — an estimated $23.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CRBU in Q3 2021 and held it in 11 quarters. The position peaked at $136K in Q3 2021. 140 funds tracked by Wall St. Rank hold CRBU as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Caribou Biosciences position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 4,652 Caribou Biosciences shares in Q2 2024, an estimated $23.9K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Caribou Biosciences in Q3 2021 and held it in 11 quarters.
Metropolitan Life Insurance Company (MetLife)'s Caribou Biosciences position peaked at $136K in Q3 2021.
140 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.